Motor Neuron Disease: Clinical Trials

123 trials for Motor Neuron Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

65 completed, 18 terminated, 13 active not recruiting, 11 recruiting. 123 Phase 3, 43 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3123Completed 65, Terminated 18, Active not recruiting 13, Recruiting 11, Unknown 9, Not yet recruiting 6, Withdrawn 1
Phase 243Completed 25, Active not recruiting 5, Recruiting 5, Not yet recruiting 3, Unknown 3, Terminated 2

Follow Motor Neuron Disease: new trials by email Literature Review of Motor Neuron Disease trials Research Report on Motor Neuron Disease

Trials (filtered) newest first · largest first

All 123 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec
Salanersen, Sham Procedure - Muscular Atrophy, Spinal
Phase 3RecruitingBiogen422026-10-312026-10-15
Efficacy and Safety of Tazbentetol in ALS Participants
Tazbentetol, placebo - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3Not yet recruitingSpinogenix4302026-10-012026-09-10
An Open Label Individual Patient (OLIP)-02 Study of Nusinersen (BIIB058)
Nusinersen Injectable Product - SMA - Spinal Muscular Atrophy
Phase 3Not yet recruitingLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's12026-09-172026-09-29
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
Salanersen - Spinal Muscular Atrophy
Phase 3RecruitingBiogen902026-09-082026-11-13
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
Rinzimetostat, Darolutamide, Enzalutamide - Metastatic Castration Resistant Prostate Cancer
Phase 3RecruitingORIC Pharmaceuticals6002026-08-032026-11-03
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Galunisertib + Nerandomilast Combination - ALS (Amyotrophic Lateral Sclerosis)
Phase 2 / Phase 3Not yet recruitingGipfel Life Sciences GmbH602026-06-302026-01-07
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
Salanersen - Muscular Atrophy, Spinal
Phase 3RecruitingBiogen302026-04-282026-10-23
HEALEY ALS Platform Trial - Regimen I NUZ-001
NUZ-001, Matching placebo - Amyotrophic Lateral Sclerosis (ALS)
Phase 2 / Phase 3Active not recruitingMerit E. Cudkowicz, MD2402026-02-252026-07-20
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Pridopidine, Placebo - Amyotrophic Lateral Sclerosis
Phase 3RecruitingPrilenia5002026-02-012026-11-17
Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients
Masitinib 4.5 mg/kg/day, Placebo, Riluzole (100 mg) - Amyotrophic Lateral Sclerosis (ALS)
Phase 3Not yet recruitingAB Science4122026-01-012025-10-03
HD-tDCS in Amyotrophic Lateral Sclerosis: A Multicenter Randomized Controlled Trial
Active HD-tDCS, Simulated HD-tDCS - Amyotrophic Lateral Sclerosis (ALS)
Phase 2 / Phase 3RecruitingUniversidade Federal do Rio Grande do Norte802025-11-282026-07-20
A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
Test drug CB03-154 5mg group, Test drug CB03-154 10mg group, Test drug CB03-154 15mg group - ALS (Amyotrophic Lateral Sclerosis)
Phase 2 / Phase 3RecruitingShanghai Zhimeng Biopharma, Inc.2402025-10-302026-09-22
Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).
vesemnogene lantuparvovec - Spinal Muscular Atrophy (SMA)
Phase 3WithdrawnLantu Biopharma2025-10-152026-09-25
Study of COYA 302 for the Treatment of ALS
COYA 302, Placebo - Amyotrophic Lateral Sclerosis (ALS)
Phase 2 / Phase 3Active not recruitingCoya Therapeutics1202025-10-012026-10-13
Efficacy and Safety of MSC-NTF (NurOwn) in Participants With Early Symptomatic ALS and Moderate Disease Presentation in ALS (ENDURANCE STUDY)
Debamestrocel - MSC-NTF (NurOwn), Placebo - Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis
Phase 3Not yet recruitingBrainstorm-Cell Therapeutics2002025-06-302025-05-22
Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Type 2 Spinal Muscular Atrophy (SMA) - Phase III
GC101 adeno-associated virus injection - SMA - Spinal Muscular Atrophy
Phase 3Active not recruitingGeneCradle Inc502025-05-272026-11-13
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Acetyl-l-carnitine, Placebo - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3RecruitingMario Negri Institute for Pharmacological Research2462025-03-262026-10-06
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
BMS-986365, Enzalutamide, Abiraterone - Metastatic Castration-resistant Prostate Cancer
Phase 3Active not recruitingCelgene9602025-03-132026-09-30
Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy
Mexiletine hydrochloride, Placebo - Spinal and Bulbar Muscular Atrophy
Phase 2 / Phase 3Active not recruitingMasahisa Katsuno682025-02-282026-11-17
RAPA-501 Therapy for ALS
RAPA-501 Autologous T stem cells - Amyotrophic Lateral Sclerosis
Phase 2 / Phase 3RecruitingRapa Therapeutics LLC412025-01-022026-09-29

Showing 20 of 123. Sign in to see all of them.

Narrower conditions

Amyotrophic Lateral Sclerosis (90)  ·  Muscular Atrophy, Spinal (26)  ·  Bulbo-Spinal Atrophy, X-Linked (8)  ·  Muscular Atrophy (8)  ·  Neuromuscular Diseases (6)  ·  Spinal Muscular Atrophies of Childhood (5)  ·  Muscular Diseases (4)  ·  Prostatic Neoplasms (3)  ·  Atrophy (2)  ·  Multiple Sclerosis (2)  ·  Neuromuscular Manifestations (2)  ·  Sialorrhea (2)  ·  Anorexia (1)  ·  Breast Neoplasms (1)

Broader conditions

Nervous System Diseases (123)  ·  Neurodegenerative Diseases (122)  ·  Spinal Cord Diseases (122)  ·  Central Nervous System Diseases (121)  ·  Neuromuscular Diseases (117)  ·  Metabolic Diseases (90)  ·  Nutritional and Metabolic Diseases (90)  ·  Proteostasis Deficiencies (90)  ·  TDP-43 Proteinopathies (90)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15)  ·  Genetic Diseases, Inborn (15)  ·  Heredodegenerative Disorders, Nervous System (15)  ·  Pathological Conditions, Signs and Symptoms (14)  ·  Signs and Symptoms (11)

Interventions

Riluzole (9)  ·  Zolgensma (7)  ·  Edaravone (6)  ·  nusinersen (6)  ·  arimoclomol (3)  ·  enzalutamide (3)  ·  masitinib (3)  ·  mecobalamin (3)  ·  pridopidine (3)  ·  sodium phenylbutyrate and taurursodiol (3)  ·  CK-2017357 (2)  ·  Dexpramipexole (2)  ·  Docetaxel (2)  ·  Lithium Carbonate (2)  ·  Memantine (2)

Sponsors

Biogen (10)  ·  Merit E. Cudkowicz, MD (9)  ·  Shionogi (5)  ·  Cytokinetics (4)  ·  Novartis Gene Therapies (4)  ·  Novartis Pharmaceuticals (4)  ·  AB Science (3)  ·  Amylyx Pharmaceuticals Inc. (3)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  Eisai Co., Ltd. (3)  ·  Hoffmann-La Roche (3)  ·  Avanir Pharmaceuticals (2)  ·  Brainstorm-Cell Therapeutics (2)  ·  Ferrer Internacional S.A. (2)  ·  Humanitas Mirasole SpA (2)

Countries

United States (71)  ·  Italy (39)  ·  France (37)  ·  Spain (37)  ·  United Kingdom (36)  ·  Belgium (35)  ·  Canada (35)  ·  Germany (34)  ·  Netherlands (28)  ·  Australia (24)  ·  Japan (24)  ·  Sweden (22)  ·  Ireland (18)  ·  Poland (18)  ·  China (11)

Top investigators

Merit Cudkowicz, MD (7)  ·  Merit Cudkowicz, MD, MSc (3)  ·  Kazunori Saeki (2)  ·  Merit Cudkowicz (2)  ·  Michael Benatar, MD PhD (2)  ·  Adrian Hepner, M.D. (1)  ·  Albert Ludolph, MD, PhD (1)  ·  Alberto Albanese, MD (1)  ·  Anthony J. Windebank, MD (1)

Results publications

PMID 34383289, PMID 25982504, PMID 31420846, PMID 34536404, PMID 38705943, PMID 40067754, PMID 40067755, PMID 40067821, PMID 14718694, PMID 15505150, PMID 17980667, PMID 19029516, PMID 19682544, PMID 19743466, PMID 20363190, PMID 20839238, PMID 21887710, PMID 23613806, PMID 24067398, PMID 25286015, PMID 25297012, PMID 27751553, PMID 27939059, PMID 28522181, PMID 28864675, PMID 28872913, PMID 28872914, PMID 28872915, PMID 28872918, PMID 28872920, PMID 29091570, PMID 29367439, PMID 29402141, PMID 29443664, PMID 30523161, PMID 30554828, PMID 30578206, PMID 30636701, PMID 30814647, PMID 30879249, PMID 31719072, PMID 31930364, PMID 32640130, PMID 33743238, PMID 34433481, PMID 34457038, PMID 34816762, PMID 35246398, PMID 35397772, PMID 35532908

NIH funding

2023 (4), 2019 (3), 2025 (3), 2014 (2), 2015 (2), 2017 (2), U01NS049640 (2), 2016 (1), 2018 (1), R01NS042759 (1)